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1. Introduction
   A wide variety of cerebral pathology, from acute ischaemic 
stroke[1], to the commonest and most important of the group, 
subarachnoid hemorrhage (SAH), or even rare entities such 
as transient global amnesia[2], has been associated with 
transient cardiac dysfunction with electrocardiographic 
(ECG) changes and simultaneous release of cardiac 
biomarkers[3]. These two findings, as well as left ventricular 
systolic dysfunction, constitute cardiac abnormalities 
that have been reported after SAH[4]. Cardiopulmonary 
complications after aneurysmal SAH negatively affect 
overall morbidity and mortality and have been linked to 
worsened clinical outcome, suggesting a role for cardiac 
monitoring and interventions[5].
   Although Cardiac tr elevation, in addition to ECG 
changes or alone, considered as an indicator of cardiac 
complications in SAH, it proves usually to be a misleading 
finding in the emergency department in the process of 
diagnosing the underlying disease. Thus tr elevation in 
SAH patients is often difficult to be appropriately assessed 
by clinicians, causing even disagreements regarding its 
management between neurosurgeons and cardiologists. But 
is this laboratory finding a rightful cause of worry about the 
patients’ cardiac function? Does it affect their prognosis 
and how? Approaching answers to these questions, purpose 
of this article was to review the literature regarding the 
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clinical interpretation of tr elevation in SAH.
   We systematically reviewed the literature regarding tr 
elevation in patients with SAH. We searched for articles 
in PubMed using the key words: “troponin elevation” and 
“subarachnoid hemorrhage”, which revealed 30 articles. All 
of them, as well as relative neurosurgical books, were used 
for this review. The available literature was mostly about 
cardiac complications following SAH. We classified the data 
we collected into two main categories; the tr elevation is 
caused by cardiac complications of SAH and the prognostic 
value of this elevation.
2. Cardiac complications of SAH
   Cardiac alterations associated with SAH have been 
recognized and frequently reported[6]. Some type of 
cardiovascular abnormality develops in most patients with 
SAH. Hypertension and hypotension are common (27% and 
18% respectively). Other cardiovascular events include life-
threatening arrhythmias (8%), myocardial ischemia (6%) and 
successful resuscitation from cardiac arrest (4%)[7].
   SAH may be associated with ECG changes in over 50% 
of cases, occasionally producing ECG abnormalities 
indistinguishable from an acute myocardial infarct[6]. 
Arrhythmias also occur in about one-third of patients after 
SAH[5].
   More specifically, SAH may cause ECG changes that 
include ST segment elevation in lateral leads, ST segment 
depression in inferior leads and T wave inversion[8,9]. In the 
study of Sommargren et al.[10], repolarization abnormalities 
occurred in 41% of SAH patients. These included prolonged 
QTc interval (>460 ms) in 16%, ST segment elevation in 
9%, ST depression in 3%, T wave inversion in 7% and U 
wave (≥100 μV) in 15%. ECG criteria for left ventricular 
hypertrophy were met in 14% and 43% of those patients who 
had no history of hypertension. They interestingly reported 
that prolonged QTc interval after SAH is significantly related 
to myocardial injury[10].
   SAH can cause transient abnormal left ventricular wall 
motion with echocardiographic findings of diffuse or 
localized left ventricular hypokinesis around the apical 
area (Takotsubo-like cardiomyopathy), but with negative 
coronary angiography[8]. Certain echocardiographic criteria 
for the diagnosis of apical balloting syndrome as a result 
of SAH (or other cerebral pathology) have been established 
(such as transient akinesis or dyskinesis of the central left 
ventricle with or without apex involvement extending over 
the region of vascularisation of more than one coronary 
artery). However, its diagnosis in the emergency department 
remains a challenge largely due to the lack of significantly 
constricted coronary vessels or angiographic features of 
atheromatous plaque rupture, together with ECG changes 
(ST segment elevation or negative T waves) and slightly 
increased concentrations of cardiac tr[11-13].
3. Underlying pathophysiological mechanisms
   The mechanisms of cardiac dysfunction after SAH used 
to be controversial until recently[4]. Historically, cardiac 
necrosis after SAH had been attributed to coronary artery 
disease, coronary vasospasm or oxygen supply-demand 
mismatch. Experimental evidence, however, indicated that 
excessive release of norepinephrine from the myocardial 
sympathetic nerves was the most likely cause[14].
   Nowadays we know that acute left ventricular dysfunction 
associated with SAH can be the expression of a stress-
related cardiomyopathy[15], (“catecholamine hypothesis” 
of neurogenic cardiac stunning causing non-ischemic 
myocardiac injury[16]). Neurogenic stunned myocardium (also 
known as apical balloting syndrome or Takotsubo syndrome) 
is a frequent complication of aneurysmal SAH, with a 
significant impact on disease course. The presumed cause is 
catecholamine surge at the time of aneurysm rupture[17]. A 
possible mechanism is that hypothalamic ischemia causes 
increased sympathetic tone and resultant catecholamine 
surge producing subendocardial ischemia or coronary artery 
vasospasm[18].
   So SAH-related cardiac complications have been 
attributed to cateholamin toxicity that could be triggered 
by physical or psychological stress. This mechanism is 
similar to acute myocardial infarction and this is probably 
the reason of both ECG abnormalities and tr release but 
with a different pathological background[3,19]. Soon after 
the event of SAH, a generalized sympathetic response 
is often encountered, which has profound effects on the 
cardiopulmonary system as well as the systemic vasculature. 
The massive surge of catecholamines after SAH likely 
induces various degrees of cardiac injury, as evidenced by 
increased serum tr T levels, ECG changes and sometimes 
severe cardiac wall motion abnormalities[20].
4. Tr elevation due to cardiac complications of SAH
   As previously mentioned, SAH frequently results in 
myocardial necrosis with release of cardiac enzymes[14]. 
Cardiac tr I release occurs frequently after SAH and has been 
associated with a neurogenic form of myocardial injury[21]. 
SAH can also cause tr T elevation accompanied by transient 
abnormal left ventricular wall motion[8,20]. Cardiac injury, 
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evidenced by an elevation in tr levels, is reported in about 
one-third of patients after aneurysmal SAH[5]. Elevated 
tr I has been reported in up to 68% of SAH patients[7]. Tr 
elevation, usually modest, is an early and specific marker 
for cardiac involvement after SAH[22,23], and its levels peak 
about two days after SAH[7].
   In the study of Kothavale et al.[4], among SAH patients with 
a peak cardiac tr I level >1.0 μg/L, 65% had regional wall 
motion abnormalities[4]. Concentration of cardiac tr <2.8 μg/
L in patients with ejection fraction <40% is characteristic for 
stunned myocardium[11].
   Lee et al.[16], reported a case that a SAH patient with 
normal myocardium perfusion (in the setting of normal 
coronary arteries on coronary angiogram) and midventricular 
akinetic segments, which is compatible with non-ischemic 
injury. The patient developed transient ST segment elevation 
on lateral ECG leads and elevated cardiac enzymes with 
creatine-kinase MB isoenzyme of 44.3 ng/mL and tr of 0.62 
ng/mL[16].
   Admission predictors of cardiac tr I elevation include 
poor clinical grade, intraventricular hemorrhage, loss 
of consciousness at ictus, global cerebral edema and a 
composite score of physiological derangement[21]. Tung et 
al.[14], found that a Hunt-Hess score >2, female sex, larger 
body surface area, left ventricular mass, lower systolic 
blood pressure, higher heart rate and phenylephrine dose 
are independent predictors of tr I elevation (>1.0 μg/L). 
They also found that the degree of neurological injury as 
measured by the Hunt-Hess grade is a strong, independent 
predictor of myocardial necrosis after SAH, supporting 
the hypothesis that cardiac injury after SAH is a neurally 
mediated process[14]. Moreover, Sommargren et al.[10], found 
that serum cardiac tr I was elevated in 21% SAH patients 
with abnormalities on the initial ECG. Controlling for 
gender, those with QTc interval >460 ms were 5.5 times more 
likely to have elevated serum cardiac tr I[10]. Tr elevation 
predictors in aneurysmal SAH patients are poor clinical 
grade, intraventricular hemorrhage,  global cerebral edema, 
female sex, large body surface area, left ventricular mass, 
lower systolic blood pressure, higher heart rate, prolonged 
qtc interval, composite score of physiological derangement 
and phenylephrine dose.
   Furthermore, levels of troponin Ic (and Serum B-type 
natriuretic peptide) are correlated and seem to be more 
sensitive to cardiac stress occurring in SAH as compared 
with Doppler variables of diastolic function[24].
   Interestingly, cardiac tr I (and creatine kinase MB) levels 
in blood (and pericardial fluid) show also a mild and gradual 
postmortem time-dependent elevation, larger for specific 
causes of death including cerebrovascular diseases[25].
   Of course, regarding the clinical management of SAH 
patients, early detection of cardiac involvement, through 
ECG abnormalities and tr elevation, and monitoring of 
these changes, as well as direct approach and medical 
intervention, holds an important role in amelioration of 
patient outcome[26].
5. Tr elevation as a prognostic factor in SAH
   The prognostic significance and clinical impact of cardiac 
tr I elevation used to be poorly defined until recently[21]. 
Several studies have been published concerning the use 
of tr levels in SAH as a predictor of outcome. Most of 
these studies have associated higher levels of tr with poor 
outcome[22]. Nowadays we know that cardiac tr I is a good 
indicator not only for cardiopulmonary complications 
but also for neurological complications[27], and outcome 
following SAH[22,27]. More specifically, elevated tr levels 
are associated with disability and death after SAH, as well 
as worse neurological grade, systolic and diastolic cardiac 
dysfunction and pulmonary congestion[7].
   A cardiac tr I level >1.0 μg/L is independent predictor 
for the development of regional wall motion abnormalities, 
which are, as already mentioned, frequent after SAH[4]. 
Thus left ventricular wall motion abnormalities seen on 
echocardiography are more common in patients with 
elevated tr[7].
   According to some studies, cardiac tr I elevation is also 
related with variable clinical factors such as poor Glasgow 
Outcome Scale score, profound pulmonary complication, 
higher heart rate during initial three days following SAH and 
even incidence of vasospasm and duration of hyperdynamic 
therapy for vasospasm. So this mark could contribute to 
the management of SAH and treatment of concomitant 
complications[27].
   Tanabe et al.[28] studied the levels of tr and associated 
outcomes in SAH patients. Highly positive cardiac tr I (>1.0 
ng/ml) was associated with clinical neurological severity, 
systolic and diastolic cardiac dysfunction, pulmonary 
congestion and longer intensive care unit stay. Even mild 
increases in cardiac tr I (0.1-1.0 ng/mL) were associated with 
diastolic dysfunction and pulmonary congestion[28].
   In the study of Naidech et al.[21] peak cardiac tr I level was 
associated with an increased risk of echocardiographic left 
ventricular dysfunction, pulmonary edema, hypotension 
requiring pressors and delayed cerebral ischemia from 
vasospasm. Peak cardiac tr I levels were predictive of death 
or severe disability at discharge after controlling for age, 
clinical grade, and aneurysm size but this association was 
no longer significant at 3 months. Cardiac tr I elevation after 
SAH was also associated with an increased risk of death or 
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poor functional outcome at discharge[21].
   In the same direction, Kumar et al.[23] showed that 
neurological outcome was adversely related to increase in tr 
levels and Ahmadian et al.[22] reported that associated levels 
of tr >1 μg/L are ten times higher risk of death. Interestingly, 
Ramappa et al.[29] found out that patients with SAH and 
elevated cardiac tr I usually have worse neurological status 
at admission, as well as a worse neurological outcome and 
in-hospital mortality[29]. As prognostic factors, clinical 
parameters are disability, mortality, worse neurological 
grade, systolic cardiac dysfunction, diastolic cardiac 
dysfunction, higher heart rate during initial three days 
following sah, pulmonary congestion, longer intensive care 
unit stay, incidence of vasospasm, duration of hyperdynamic 
therapy for vasospasm, and poor functional outcome at 
discharge from some published reports.
   Additionally, Martini et al.[30] found that tr elevation >0.4 
ng/mL was one of some important factors (such as age, 
Hunt-Hess and Fisher scores and mechanical ventilation 
at intensive care unit admission), which were adjusted with 
the usage of multivariable logistic regression to come to the 
conclusion that patients with SAH and early positive fluid 
balance had worse clinical presentation, prolonged length 
of hospital stay and greater resource use during the hospital 
course[30].
   On the other hand, other analyses failed to prove a 
predictive value of elevated tr in SAH patients. Gupte 
et al.[31], for example, although associated high tr levels 
with higher in-hospital mortality, statistically significant 
difference was not proven when results were adjusted for 
age and Hunt-Hess and Fisher grades[31]. Furthermore, 
though Sanchez-Peña et al.[32], initially observed that tr 
initial value was associated, among other factors, with poor 
12-month outcome (namely Glasgow Outcome Scale 1-3), 
they concluded, after multivariate analysis, that only mean 
15-day S100-B value significantly predicted outcome[32]. 
Finally, according to Pereira et al.[33], only persistent 
intracranial pressure elevation and higher mean 8-day 
S100-B value significantly and independently predicted a 
poor outcome after one year[33].
6. Conclusion
   Neurogenic stunned myocardium is a frequent 
complication of aneurysmal SAH due to catecholamine 
surge and tr elevation which is a common finding in 
aneurysmal SAH patients. Answering our purpose’s 
questions, we could say that this laboratory finding is a 
definitely rightful cause of worry about the patients’ cardiac 
function and prognosis. More specifically, tr elevation, 
usually modest, is an early and specific marker for cardiac 
involvement after SAH and its levels peak about two days 
after SAH. Predictors of cardiac tr I elevation include 
poor clinical grade, intraventricular hemorrhage, loss of 
consciousness at ictus, global cerebral edema, female sex, 
large body surface area, lower systolic blood pressure, 
higher heart rate and prolonged QTc interval. Elevated tr 
levels are associated with disability and death (especially 
tr >1 μg/L), worse neurological grade, systolic and diastolic 
cardiac dysfunction, pulmonary congestion, longer intensive 
care unit stay and even the incidence of vasospasm (an often 
devastating neurological consequence of aneurysmal SAH). 
Tr elevation should be therefore early detected, carefully 
monitored and appropriately managed by a multidisciplinary 
team of clinicians.
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